Abivax S.A. is a French biotech company developing new medicines.
Abivax S.A. (ABVX) is expected to report earnings on Monday, September 21, 2026, after the close. Estimated release time after close. Consensus EPS estimate is $-0.96.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2025-09-08 | FY2025 Q2 | $-0.90 | $-1.59 | -76.7% | $0 |
| 2025-03-24 | FY2024 Q4 | $-0.76 | $-1.50 | -98.5% | $0 |
| 2024-06-30 | FY2024 Q2 | — | $-0.65 | — | $0 |
| 2023-12-31 | FY2023 Q4 | — | $-1.98 | — | $2.33M |
| 2023-06-30 | FY2023 Q2 | — | $-1.45 | — | $2.25M |
| 2022-12-31 | FY2022 Q4 | $-1.93 | $-1.81 | +6.2% | $2.25M |
| 2022-06-30 | FY2022 Q2 | — | $-1.76 | — | $2.23M |
| 2021-12-31 | FY2021 Q4 | — | $-1.48 | — | $0 |
ABVX has beaten consensus EPS in 1 of its last 8 reported quarters.
See ABVX on the live calendar →